Validating the PROMIS cognitive function short form in cancer survivors

By sjmartinez • June 18, 2023

Henneghan AM, Van Dyk K, Zhou X, Moore RC, Root JC, Ahles TA, Nakamura ZM, Mandeblatt J, Ganz PA. Validating the PROMIS cognitive function short form in cancer survivors. Breast Cancer Res Treat. 2023 Jun 17. doi: 10.1007/s10549-023-06968-2. Epub ahead of print. PMID: 37330430.

Tags: Cancer-related cognitive impairment, Convergent validity, Hematology/Oncology, Internal reliability, PROMIS cognition, Publications, Self-report

Related Posts

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia

Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C,[...]

Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering

Chen X, Mao Z, Kolawole EM, Persechino M, Jude KM, Ogishi M, Mo KC, McLaughlin J, Cheng D, Xiang X, Yang X, Gee C, Liu[...]

A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design

Ji J, Crespi CM, Yee L, Zekster YA, Al-Saleem A, Petersen L, Lee C, Son N, Smith C, Evans T, Tchkonia T, Kirkland JL, Kuchel[...]